Atria Investments Inc Buys New Holdings in Masimo Co. (NASDAQ:MASI)

Atria Investments Inc purchased a new position in Masimo Co. (NASDAQ:MASI) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,026 shares of the medical equipment provider’s stock, valued at approximately $335,000.

Other institutional investors also recently bought and sold shares of the company. Charles Schwab Investment Management Inc. grew its position in Masimo by 2.1% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 377,836 shares of the medical equipment provider’s stock worth $62,456,000 after purchasing an additional 7,808 shares during the period. SBI Securities Co. Ltd. acquired a new stake in Masimo during the fourth quarter worth about $46,000. Jones Financial Companies Lllp purchased a new position in Masimo during the fourth quarter valued at approximately $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in Masimo in the fourth quarter valued at approximately $67,000. Finally, Smartleaf Asset Management LLC lifted its holdings in Masimo by 31.6% in the fourth quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 60 shares during the period. 85.96% of the stock is owned by hedge funds and other institutional investors.

Masimo Stock Up 2.7 %

Shares of NASDAQ MASI opened at $172.78 on Tuesday. Masimo Co. has a 52-week low of $101.61 and a 52-week high of $194.88. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. The company’s 50-day simple moving average is $174.86 and its 200-day simple moving average is $158.33. The firm has a market cap of $9.32 billion, a price-to-earnings ratio of 119.16 and a beta of 1.04.

Masimo (NASDAQ:MASI) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 EPS for the quarter, topping the consensus estimate of $1.42 by $0.38. The company had revenue of $600.70 million during the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. Equities analysts predict that Masimo Co. will post 4.1 EPS for the current fiscal year.

Insider Activity at Masimo

In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the company’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at $4,048,568.28. This represents a 55.38 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Craig B. Reynolds sold 2,053 shares of Masimo stock in a transaction on Friday, March 14th. The stock was sold at an average price of $166.13, for a total value of $341,064.89. Following the transaction, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

MASI has been the subject of several recent research reports. Stifel Nicolaus reaffirmed a “buy” rating and set a $190.00 target price (up from $170.00) on shares of Masimo in a report on Friday, November 22nd. Raymond James lifted their price objective on shares of Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a report on Friday, December 27th. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Wells Fargo & Company lifted their price target on Masimo from $193.00 to $205.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Finally, Piper Sandler increased their price target on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $194.80.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.